<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01500018</url>
  </required_header>
  <id_info>
    <org_study_id>D4130C00022</org_study_id>
    <nct_id>NCT01500018</nct_id>
  </id_info>
  <brief_title>Study in Healthy Recreational Polydrug Users to Measure the Abuse Potential of TC-5214</brief_title>
  <acronym>TC-5214</acronym>
  <official_title>A Single-center, Single-dose, Double-blind, Randomized, Placebo- and Active-controlled Crossover Study to Evaluate the Abuse Potential of TC-5214 in Healthy Recreational Polydrug Users</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      This is a single dose, crossover study to assess the abuse potential of TC-5214 compared to
      placebo, ketamine, and phentermine in healthy recreational polydrug users.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Single-center, Single-dose, Double-blind, Randomized, Placebo- and Active-controlled
      Crossover Study to Evaluate the Abuse Potential of TC-5214 in Healthy Recreational Polydrug
      Users.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Sponsor decision to withdraw.
  </why_stopped>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">April 2012</completion_date>
  <primary_completion_date type="Anticipated">April 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Momentary Drug Liking VAS maximum effect (Emax)</measure>
    <time_frame>0.5, 1,1.5, 2, 2.5, 3, 4, 6, 8, 10 and 24 hours post dose</time_frame>
    <description>Visual analogue scale from 0 to 100 mm. The statement put is: &quot;At this moment, my liking for this drug is&quot; with anchor points &quot;0: Strong disliking&quot; and &quot;100: Strong liking&quot;. The maximum value recorded is chosen.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Momentary Drug Liking VAS minimum effect (Emin)</measure>
    <time_frame>0.5, 1,1.5, 2, 2.5, 3, 4, 6, 8, 10 and 24 hours post dose</time_frame>
    <description>Visual analogue scale from 0 to 100 mm. The statement put is: &quot;At this moment, my liking for this drug is&quot; with anchor points &quot;0: Strong disliking&quot; and &quot;100: Strong liking&quot; The minimum value recorded is chosen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug Liking VAS time-weighted mean (TWmean)</measure>
    <time_frame>0.5, 1,1.5, 2, 2.5, 3, 4, 6, 8, 10 and 24 hours post dose</time_frame>
    <description>Visual analogue scale from 0 to 100 mm. The statement put is: &quot;At this moment, my liking for this drug is&quot; with anchor points &quot;0: Strong disliking&quot; and &quot;100: Strong liking&quot;. Time weighted average score is calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Drug Liking VAS maximum effect ( Emax)</measure>
    <time_frame>0.5, 1,1.5, 2, 2.5, 3, 4, 6, 8, 10 and 24 hours post dose</time_frame>
    <description>Visual analogue scale from 0 to 100 mm. The statement put is: &quot;Overall, my liking for this drug is&quot; with anchor points &quot;0: Strong disliking&quot; and &quot;100: Strong liking&quot;. The maximum value recorded is chosen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Drug Liking VAS (Emin)</measure>
    <time_frame>0.5, 1,1.5, 2, 2.5, 3, 4, 6, 8, 10 and 24 hours post dose</time_frame>
    <description>Visual analogue scale from 0 to 100 mm. The statement put is: &quot;Overall, my liking for this drug is&quot; with anchor points &quot;0: Strong disliking&quot; and &quot;100: Strong liking&quot;. The minimum value recorded is chosen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Drug Liking VAS 10-hour mean score</measure>
    <time_frame>0.5, 1,1.5, 2, 2.5, 3, 4, 6, 8 and 10 hours post dose</time_frame>
    <description>Visual analogue scale from 0 to 100 mm. The statement put is: &quot;Overall, my liking for this drug is&quot; with anchor points &quot;0: Strong disliking&quot; and &quot;100: Strong liking&quot;. The mean value is calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Drug Liking VAS 24-hour mean score</measure>
    <time_frame>0.5, 1,1.5, 2, 2.5, 3, 4, 6, 8, 10 and 24 hours post dose</time_frame>
    <description>Visual analogue scale from 0 to 100 mm. The statement put is: &quot;Overall, my liking for this drug is&quot; with anchor points &quot;0: Strong disliking&quot; and &quot;100: Strong liking&quot;. The mean value is calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Take Drug Again VAS Emax</measure>
    <time_frame>0.5, 1,1.5, 2, 2.5, 3, 4, 6, 8, 10 and 24 hours post dose</time_frame>
    <description>Visual analogue scale from 0 to 100 mm. The statement put is: &quot;I would take this drug again&quot; with anchor points &quot;0: Definitely not&quot; and &quot;100: Definitely so&quot;. The maximum value recorded is chosen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Take Drug Again VAS 10-hour mean score</measure>
    <time_frame>0.5, 1,1.5, 2, 2.5, 3, 4, 6, 8 and 10 hours post dose</time_frame>
    <description>Visual analogue scale from 0 to 100 mm. The statement put is: &quot;I would take this drug again&quot; with anchor points &quot;0: Definitely not&quot; and &quot;100: Definitely so&quot;. The mean value is calculated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Take Drug Again VAS 24-hour mean score</measure>
    <time_frame>0.5, 1,1.5, 2, 2.5, 3, 4, 6, 8, 10 and 24 hours post dose</time_frame>
    <description>Visual analogue scale from 0 to 100 mm. The statement put is: &quot;I would take this drug again&quot; with anchor points &quot;0: Definitely not&quot; and &quot;100: Definitely so&quot;. The mean value is calculated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective Drug Value Emax</measure>
    <time_frame>10 and 24 hours post dose</time_frame>
    <description>The SDV is a proxy measure of reinforcing efficacy that involves a series of independent, theoretical forced choices between the drug administered and different monetary values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective Drug Value 10 hour mean score</measure>
    <time_frame>10 hours post dose</time_frame>
    <description>The SDV is a proxy measure of reinforcing efficacy that involves a series of independent, theoretical forced choices between the drug administered and different monetary values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective Drug 24 hour mean scores</measure>
    <time_frame>10 and 24 hours post dose</time_frame>
    <description>The SDV is a proxy measure of reinforcing efficacy that involves a series of independent, theoretical forced choices between the drug administered and different monetary values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High VAS Emax</measure>
    <time_frame>0.5, 1,1.5, 2, 2.5, 3, 4, 6, 8, 10 and 24 hours post dose</time_frame>
    <description>Visual analogue scale from 0 to 100 mm. The statement put is: &quot;I am feeling high&quot; with anchor points &quot;0: Definitely not&quot; and &quot;100: Definitely so&quot;. The maximum value recorded is chosen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High VAS TWmean</measure>
    <time_frame>0.5, 1,1.5, 2, 2.5, 3, 4, 6, 8, 10 and 24 hours post dose</time_frame>
    <description>Visual analogue scale from 0 to 100 mm. The statement put is: &quot;I am feeling high&quot; with anchor points &quot;0: Definitely not&quot; and &quot;100: Definitely so&quot;. Time weighted average score is calculated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Good Effects VAS Emax</measure>
    <time_frame>0.5, 1,1.5, 2, 2.5, 3, 4, 6, 8, 10 and 24 hours post dose</time_frame>
    <description>Visual analogue scale from 0 to 100 mm. The statement put is: &quot;I can feel good drug effects&quot; with anchor points &quot;0: Definitely not&quot; and &quot;100: Definitely so&quot;. The maximum value recorded is chosen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Good Effects VAS TWmean</measure>
    <time_frame>0.5, 1,1.5, 2, 2.5, 3, 4, 6, 8, 10 and 24 hours post dose</time_frame>
    <description>Visual analogue scale from 0 to 100 mm. The statement put is: &quot;I can feel good drug effects&quot; with anchor points &quot;0: Definitely not&quot; and &quot;100: Definitely so&quot;. Time weighted average score is calculated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Addiction Research Center Inventory (ARCI) euphoria scale (MBG) Emax</measure>
    <time_frame>0.5, 1,1.5, 2, 2.5, 3, 4, 6, 8, 10 and 24 hours post dose</time_frame>
    <description>Questionnaire to assess possible addiction. The maximum value recorded is chosen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Addiction Research Center Inventory (ARCI) euphoria scale (MBG) TWmean</measure>
    <time_frame>0.5, 1,1.5, 2, 2.5, 3, 4, 6, 8, 10 and 24 hours post dose</time_frame>
    <description>Questionnaire to assess possible addiction. The time-weighted mean value is calculated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bad Effects VAS Emax</measure>
    <time_frame>0.5, 1,1.5, 2, 2.5, 3, 4, 6, 8, 10 and 24 hours post dose</time_frame>
    <description>Visual analogue scale from 0 to 100 mm. The statement put is: &quot;I can feel bad drug effects&quot; with anchor points &quot;0: 0: Definitely not&quot; and &quot;100: 0: Definitely so&quot;. The maximum value recorded is chosen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bad Effects VAS TWmean</measure>
    <time_frame>0.5, 1,1.5, 2, 2.5, 3, 4, 6, 8, 10 and 24 hours post dose</time_frame>
    <description>Visual analogue scale from 0 to 100 mm. The statement put is: &quot;I can feel bad drug effects&quot; with anchor points &quot;0: Definitely not&quot; and &quot;100: Definitely so&quot;. Time weighted average score is calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ARCI dysphoria scale (LSD) Emax</measure>
    <time_frame>0.5, 1,1.5, 2, 2.5, 3, 4, 6, 8, 10 and 24 hours post dose</time_frame>
    <description>Questionnaire to assess possible addiction. The maximum value recorded is chosen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ARCI dysphoria scale (LSD) TWmean</measure>
    <time_frame>0.5, 1,1.5, 2, 2.5, 3, 4, 6, 8, 10 and 24 hours post dose</time_frame>
    <description>Questionnaire to assess possible addiction. The time-weighted mean value is calculated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ARCI sedation scale (PCAG) Emax</measure>
    <time_frame>0.5, 1,1.5, 2, 2.5, 3, 4, 6, 8, 10 and 24 hours post dose</time_frame>
    <description>Questionnaire to assess possible addiction. The maximum value recorded is chosen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ARCI sedation scale (PCAG) TWmean</measure>
    <time_frame>0.5, 1,1.5, 2, 2.5, 3, 4, 6, 8, 10 and 24 hours post dose</time_frame>
    <description>Questionnaire to assess possible addiction. The time-weighted mean value is calculated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alertness/Drowsiness VAS Emin (drowsiness)</measure>
    <time_frame>0.5, 1,1.5, 2, 2.5, 3, 4, 6, 8, 10 and 24 hours post dose</time_frame>
    <description>Visual analogue scale from 0 to 100 mm. The statement put is: &quot;I am feeling&quot; with anchor points &quot;0: Very Drowsy&quot; and &quot;100: Very Alert&quot;. The minimum value recorded is chosen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alertness/Drowsiness VAS TWmean</measure>
    <time_frame>0.5, 1,1.5, 2, 2.5, 3, 4, 6, 8, 10 and 24 hours post dose</time_frame>
    <description>Visual analogue scale from 0 to 100 mm. The statement put is: &quot;I am feeling&quot; with anchor points &quot;0: Very Drowsy&quot; and &quot;100: Very Alert&quot;. The time weighted mean value is calculated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any Effects VAS Emax</measure>
    <time_frame>0.5, 1,1.5, 2, 2.5, 3, 4, 6, 8, 10 and 24 hours post dose</time_frame>
    <description>Visual analogue scale from 0 to 100 mm. The statement put is: &quot;I can feel any drug effects&quot; with anchor points &quot;0: 0: Definitely not&quot; and &quot;100: 0: Definitely so&quot;. The maximum value recorded is chosen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any Effects VAS TWmean</measure>
    <time_frame>0.5, 1,1.5, 2, 2.5, 3, 4, 6, 8, 10 and 24 hours post dose</time_frame>
    <description>Visual analogue scale from 0 to 100 mm. The statement put is: &quot;I can feel any drug effects&quot; with anchor points &quot;0: 0: Definitely not&quot; and &quot;100: 0: Definitely so&quot;. The time-weighted mean value is calculated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bowdle VAS Emax</measure>
    <time_frame>0.5, 1,1.5, 2, 2.5, 3, 4, 6, 8, 10 and 24 hours post dose</time_frame>
    <description>13 items for which the volunteer is asked to rate his/her feelings over the past 30 minutes. Each VAS will be scored from 0 to 100, with 0 reflecting &quot;Not at all&quot; and 100 reflecting &quot;Extremely&quot;. The maximum value recorded is chosen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bowdle VAS TWmean</measure>
    <time_frame>0.5, 1,1.5, 2, 2.5, 3, 4, 6, 8, 10 and 24 hours post dose</time_frame>
    <description>13 items for which the volunteer is asked to rate his/her feelings over the past 30 minutes. Each VAS will be scored from 0 to 100, with 0 reflecting &quot;Not at all&quot; and 100 reflecting &quot;Extremely&quot;. The time-weighted mean value is calculated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ARCI A scale Emax</measure>
    <time_frame>0.5, 1,1.5, 2, 2.5, 3, 4, 6, 8, 10 and 24 hours post dose</time_frame>
    <description>Questionnaire to assess possible addiction. The maximum value recorded is chosen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ARCI A scale TWmean</measure>
    <time_frame>0.5, 1,1.5, 2, 2.5, 3, 4, 6, 8, 10 and 24 hours post dose</time_frame>
    <description>Questionnaire to assess possible addiction. The time-weighted mean value is calculated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ARCI Phentermine and Benzedrine Group scale (BG) Emax</measure>
    <time_frame>0.5, 1,1.5, 2, 2.5, 3, 4, 6, 8, 10 and 24 hours post dose</time_frame>
    <description>Questionnaire to assess possible addiction. The maximum value recorded is chosen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ARCI Phentermine and Benzedrine Group scale (BG) TWmean</measure>
    <time_frame>0.5, 1,1.5, 2, 2.5, 3, 4, 6, 8, 10 and 24 hours post dose</time_frame>
    <description>Questionnaire to assess possible addiction. The time-weighted mean value is calculated</description>
  </secondary_outcome>
  <number_of_arms>14</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Drug Abuse</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Crossover Treatment Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Placebo, Period 2: Phentermine 45 mg, Period 3: Phentermine 90 mg, Period 4: Ketamine 100 mg, Period 5: TC-5214 2 mg, Period 6: TC-5214 8 mg, Period 7: TC-5214 16 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Crossover Treatment Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Phentermine 45 mg, Period 2: Ketamine 100 mg , Period 3: Placebo, Period 4: TC-5214 8 mg , Period 5: Phentermine 90 mg, Period 6: TC-5214 16 mg, Period 7: TC-5214 2 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Crossover Treatment Sequence 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Ketamine 100 mg, Period 2: TC-5214 8 mg, Period 3: Phentermine 45 mg, Period 4: TC-5214 16 mg, Period 5: Placebo, Period 6: TC-5214 2 mg, Period 7: Phentermine 90 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Crossover Treatment Sequence 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: TC-5214 8 mg, Period 2: TC-5214 16 mg, Period 3: Ketamine 100 mg, Period 4: TC-5214 2 mg, Period 5: Phentermine 45 mg , Period 6: Phentermine 90 mg, Period 7: Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Crossover Treatment Sequence 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: TC-5214 16 mg, Period 2: TC-5214 2 mg, Period 3: TC-5214 8 mg, Period 4: Phentermine 90 mg, Period 5: Ketamine 100 mg, Period 6: Placebo , Period 7: Phentermine 45 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Crossover Treatment Sequence 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: TC-5214 2 mg, Period 2: Phentermine 90 mg, Period 3: TC-5214 16 mg, Period 4: Placebo, Period 5: TC-5214 8 mg, Period 6:Phentermine 45 mg , Period 7: Ketamine 100 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Crossover Treatment Sequence 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Phentermine 90 mg, Period 2: Placebo, Period 3: TC-5214 2 mg, Period 4: Phentermine 45 mg, Period 5: TC-5214 16 mg, Period 6: Ketamine 100 mg, Period 7: TC-5214 8 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Crossover Treatment Sequence 8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: TC-5214 16 mg, Period 2: TC-5214 8 mg, Period 3: TC-5214 2 mg, Period 4: Ketamine 100 mg, Period 5: Phentermine 90 mg, Period 6: Phentermine 45 mg, Period 7: Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Crossover Treatment Sequence 9</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: TC-5214 2 mg, Period 2: TC-5214 16 mg, Period 3: Phentermine 90 mg, Period 4: TC-5214 8 mg, Period 5: Placebo, Period 6: Ketamine 100 mg, Period 7:
Phentermine 45 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Crossover Treatment Sequence 10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Phentermine 90 mg, Period 2: TC-5214 2 mg, Period 3: Placebo, Period 4: TC-5214 16 mg Ketamine 100 mg, Period 5: Phentermine 45 mg, Period 6: TC-5214 8 mg, Period 7: TC-5214 2 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Crossover Treatment Sequence 11</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Placebo, Period 2: Phentermine 90 mg, Period 3:Phentermine 45 mg, Period 4: TC-5214 2 mg, Period 5: Ketamine 100 mg, Period 6: TC-5214 16 mg, Period 7: TC-5214 8 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Crossover Treatment Sequence 12</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Phentermine 45 mg, Period 2: Placebo, Period 3: Ketamine 100 mg, Period 4:Phentermine 90 mg, Period 5: TC-5214 8 mg, Period 6: TC-5214 2 mg, Period 7: TC-5214 16 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Crossover Treatment Sequence 13</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Ketamine 100 mg, Period 2: Phentermine 45 mg, Period 3: TC-5214 8 mg, Period 4: Placebo, Period 5: TC-5214 16 mg, Period 6: Phentermine 90 mg, Period 7: TC-5214 2 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Crossover Treatment Sequence 14</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: TC-5214 8 mg, Period 2: Ketamine 100 mg, Period 3: TC-5214 16 mg, Period 4: Phentermine 45 mg, Period 5: TC-5214 2 mg, Period 6: Placebo, Period 7: Phentermine 90 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TC-5214</intervention_name>
    <description>Single oral dose of 2 mg</description>
    <arm_group_label>Crossover Treatment Sequence 1</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 2</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 3</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 4</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 5</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 6</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 7</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 8</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 9</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 10</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 11</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 12</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 13</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 14</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TC-5214 Placebo</intervention_name>
    <description>Single oral dose</description>
    <arm_group_label>Crossover Treatment Sequence 1</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 2</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 3</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 4</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 5</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 6</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 7</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 8</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 9</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 10</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 11</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 12</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 13</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 14</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>Single oral dose of 100 mg</description>
    <arm_group_label>Crossover Treatment Sequence 1</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 2</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 3</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 4</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 5</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 6</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 7</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 8</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 9</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 10</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 11</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 12</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 13</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 14</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phentermine</intervention_name>
    <description>Single oral dose of 45 mg</description>
    <arm_group_label>Crossover Treatment Sequence 1</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 2</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 3</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 4</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 5</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 6</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 7</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 8</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 9</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 10</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 11</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 12</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 13</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 14</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TC-5214</intervention_name>
    <description>Single oral dose of 8 mg</description>
    <arm_group_label>Crossover Treatment Sequence 1</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 2</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 3</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 4</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 5</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 6</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 7</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 8</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 9</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 10</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 11</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 12</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 13</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 14</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TC-5214</intervention_name>
    <description>Single oral dose of 16 mg</description>
    <arm_group_label>Crossover Treatment Sequence 1</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 2</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 3</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 4</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 5</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 6</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 7</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 8</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 9</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 10</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 11</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 12</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 13</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 14</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phentermine</intervention_name>
    <description>Single oral dose of 90 mg</description>
    <arm_group_label>Crossover Treatment Sequence 1</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 2</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 3</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 4</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 5</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 6</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 7</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 8</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 9</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 10</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 11</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 12</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 13</arm_group_label>
    <arm_group_label>Crossover Treatment Sequence 14</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Current recreational polydrug users with experience with at least 2 drug classes of
             abuse.

          -  At least 10 lifetime uses of stimulants drugs (eg, amphetamine, cocaine,
             methamphetamine) and 10 lifetime occasions of recreational use of psychedelic drugs
             (eg, cannabis, ketamine, dextromethorphan, PCP, MDMA [ecstasy], LSD, mesacline, or
             psilocybin).

          -  Recreational use of other classes of drugs is permitted, including opioids (eg,
             codeine, morphine, or heroin), minor tranquilizers, or sedatives (eg, benzodiazepines
             or barbiturates).

          -  Male or female volunteers aged 18 to 55, inclusive with a body mass index (BMI) within
             the range of 19.0 to 33.0 kg/m2, inclusive, and a minimum weight of 50.0 kg at
             screening.

          -  Must pass qualification phase eligibility criteria.

        Exclusion Criteria:

          -  Self-reported history of drug or alcohol dependence (except caffeine) in the past 12
             months, including subjects who have ever been in a drug rehabilitation program (other
             than treatment for smoking cessation).

          -  Unwillingness or inability to abstain from recreational drug use for the duration of
             the study from screening until follow-up.

          -  Positive for hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) at
             screening.

          -  Any significant unstable hepatic, renal, pulmonary, cardiovascular, ophthalmologic,
             neurologic, or any other medical conditions that might confound the study or put the
             volunteer at greater risk during study participation.

          -  Currently smoking more than 20 cigarettes (or 2 cigars) per day, and/or unwillingness
             to abstain from smoking for durations of at least 12 hours.

          -  Use of tobacco cessation product within 1 month (eg, nicotine substitution products,
             bupropion, etc).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hans A Eriksson, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca Kvzmbergagatan 12, 15185,Sodertalje, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pierre Geoffroy, MDCM, MSC, FCFP</last_name>
    <role>Principal Investigator</role>
    <affiliation>INC Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Brendan Smyth, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca 180 Concord Pike, Wilmington,DE 19850-5437</affiliation>
  </overall_official>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 6, 2011</study_first_submitted>
  <study_first_submitted_qc>December 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 26, 2011</study_first_posted>
  <last_update_submitted>March 21, 2012</last_update_submitted>
  <last_update_submitted_qc>March 21, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 22, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase I</keyword>
  <keyword>healthy recreational polydrug users</keyword>
  <keyword>abuse liability</keyword>
  <keyword>TC-5214</keyword>
  <keyword>Single dose crossover study to evaluate the abuse potential of TC-5214</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Substance-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
    <mesh_term>Phentermine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

